Christoph Pohl Selected Research

Interferon beta-1b (Betaseron)

1/2019	Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
9/2016	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
12/2015	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
11/2015	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
3/2014	Vitamin D as an early predictor of multiple sclerosis activity and progression.
10/2012	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.
5/2012	Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
2/2012	Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
11/2009	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
10/2009	250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christoph Pohl Research Topics

Disease

16	Multiple Sclerosis 01/2019 - 01/2007
3	Hypertension (High Blood Pressure) 01/2015 - 01/2005
2	Diabetes Mellitus 11/2006 - 01/2005
1	Osteoarthritis 01/2016
1	Fatigue 11/2014
1	Rheumatoid Arthritis 11/2014
1	Wounds and Injuries (Trauma) 09/2013
1	Demyelinating Diseases (Demyelinating Disease) 12/2011
1	Embolic Stroke 06/2010
1	Ischemic Stroke 06/2010
1	Stroke (Strokes) 06/2010
1	Relapsing-Remitting Multiple Sclerosis 10/2009
1	Injection Site Reaction 10/2009
1	Pathologic Constriction (Stenosis) 01/2005
1	Hypercholesterolemia 01/2005
1	Neoplasms (Cancer) 02/2003
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2003
1	Lymphoma (Lymphomas) 02/2003

Drug/Important Bio-Agent (IBA)

12	Interferon beta-1b (Betaseron)FDA Link 01/2019 - 08/2007
2	AntibodiesIBA 01/2019 - 01/2007
2	InterferonsIBA 01/2019 - 05/2012
2	ametantrone (HAQ)IBA 01/2016 - 11/2014
2	Vitamin D FDA LinkGeneric 12/2015 - 03/2014
2	25-hydroxyvitamin DIBA 12/2015 - 08/2014
2	hydroxide ionIBA 12/2015 - 08/2014
2	Immunoglobulin G (IgG)IBA 11/2015 - 01/2007
2	Interferon-betaIBA 06/2012 - 08/2007
2	Neutralizing AntibodiesIBA 06/2012 - 02/2012
2	Factor XIII (Coagulation Factor XIII)IBA 06/2010 - 01/2005
2	Lipoprotein(a)IBA 11/2006 - 01/2005
1	SodiumIBA 07/2017
1	SaltsIBA 07/2017
1	CotinineIBA 11/2015
1	Biomarkers (Surrogate Marker)IBA 11/2015
1	DipeptidesIBA 01/2015
1	Tryptophan (L-Tryptophan)FDA Link 01/2015
1	Guanosine Diphosphate (GDP)IBA 11/2014
1	RNA (Ribonucleic Acid)IBA 12/2011
1	factor V LeidenIBA 06/2010
1	Prothrombin (Factor II)IBA 06/2010
1	Glatiramer Acetate (Copaxone)FDA Link 10/2009
1	Immunoglobulin M (IgM)IBA 01/2007
1	Myelin-Oligodendrocyte GlycoproteinIBA 01/2007
1	Myelin Basic ProteinIBA 01/2007
1	CreatinineIBA 11/2006
1	HDL CholesterolIBA 01/2005
1	Factor VIII (Coagulation Factor VIII)IBA 01/2005
1	Fibrinogen (Factor I)FDA Link 01/2005
1	HDL LipoproteinsIBA 01/2005
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2005
1	Nicotine FDA Link 01/2005
1	Triglycerides (Triacylglycerol)IBA 01/2005
1	von Willebrand FactorIBA 01/2005
1	oxidized low density lipoproteinIBA 01/2005

Therapy/Procedure

2	Therapeutics 06/2012 - 02/2003
2	Treatment Delay 05/2012 - 11/2009
1	Splenectomy 09/2013
1	Blood Transfusion (Blood Transfusions) 09/2013
1	Adjuvant Chemotherapy 02/2003
1	Neoadjuvant Therapy 02/2003
1	Drug Therapy (Chemotherapy) 02/2003